Last month the FDA approved the Guardant Shield Blood Collection Kit as an early, noninvasive, and accessible preliminary screening test for colorectal cancer (CRC). It has limited detection accuracy, but “some screening is better than no screening,” says anatomic pathologist Adam Booth. The Focus spoke to Adam Booth, MD to get his thoughts on the Guardant Shield Blood Collection Kit’s FDA approval. He highlighted the test’s limitations, including its insensitivity when detecting advanced precancerous lesions, but was broadly positive about the rollout of any kind of test that “removes potenti…